Vicapsys Life Sciences, Inc.

VICP

US92560A1060

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:40:10 2024-04-22 pm EDT			5-day change	1st Jan Change
0.9799 ^USD	+58.05%		+58.05%	-64.24%

2023	Vicapsys Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Vicapsys Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Vicapsys Life Sciences, Inc. announced that it has received $0.3036 million in funding

June 27, 2023

On June 28, 2023, Vicapsys Life Sciences, Inc. closed the transaction. The company issued securities from 1 investors pursuant to exemption provided under regulation D.

Latest news about Vicapsys Life Sciences, Inc.

Vicapsys Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Vicapsys Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Vicapsys Life Sciences, Inc. announced that it has received $0.3036 million in funding	23-06-27	CI
Vicapsys Life Sciences, Inc. announced that it expects to receive $0.3036 million in funding	23-06-26	CI
Vicapsys Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Vicapsys Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Vicapsys Life Sciences, Inc. Auditor Raises 'Going Concern' Doubt	23-04-13	CI
Vicapsys Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-21	CI
Vicapsys Life Sciences, Inc. Announces Board Changes	22-09-28	CI
Vicapsys Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
Vicapsys Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Vicapsys Life Sciences, Inc. Appoints Federico Pier as Chief Executive Officer	22-04-12	CI
Vicapsys Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-16	CI
Vicapsys Life Sciences, Inc. Auditor Raises 'Going Concern' Doubt	22-03-15	CI
Vicapsys Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Vicapsys Life Sciences, Inc. Auditor Raises 'Going Concern' Doubt	21-09-16	CI
Vicapsys Life Sciences, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	21-09-09	CI
Vicapsys Life Sciences, Inc. announced that it has received $0.05 million in funding	18-02-15	CI
Vicapsys Life Sciences, Inc. announced a financing transaction	18-01-18	CI
ViCapsys, Inc. acquired SSGI, Inc. in a reverse merger transaction.	17-12-25	CI

Chart Vicapsys Life Sciences, Inc.

Duration

Period

More charts

Vicapsys Life Sciences, Inc. develops and commercializes, on a worldwide basis, various intellectual property rights relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. VICAPSYN is the Companyâs product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. It also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery and others.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VICAPSYS LIFE SCIENCES, INC.	-64.24%	31.43M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B